QIAGEN Inc.
27220 Turnberry Lane
Suite 200
Valencia
California
91355
United States
Tel: 800-426-8157
Fax: 800-718-2056
Website: http://www.qiagen.com/
About QIAGEN Inc.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as the "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer. The company employs more than 3,100 people in over 30 locations worldwide. QIAGEN’s North American headquarters is in Germantown, Maryland and its global headquarters is located in Hilden, Germany.
Further information about QIAGEN can be found at http://www.qiagen.com/.
114 articles about QIAGEN Inc.
-
QIAGEN Inc. Plans to Buy Cancer MDx Firm Ipsogen for $101 Million
6/15/2011
-
QIAGEN Inc. Reaches Milestone With 75 Million Deliveries of HPV Tests, Announces Strategy Update for QIAensemble Program
5/9/2011
-
Rwanda, Merck & Co., Inc. and QIAGEN Inc. Launch Africa’s First Comprehensive Cervical Cancer Prevention Program Incorporating Both HPV Vaccination and HPV Testing
4/26/2011
-
QIAGEN Inc. Makes Proposal to Acquire Australian Diagnostics Company Cellestis Inc. for $355 Million
4/5/2011
-
QIAGEN Inc. Launches Kit for DNA Quantification in Forensic Samples
3/22/2011
-
Epigenomics AG and QIAGEN Inc. Sign Collaboration Agreement in Colorectal Cancer Blood Testing
2/28/2011
-
QIAGEN Inc. Establishes Subsidiary in India to Accelerate Expansion
1/27/2011
-
QIAGEN Inc. to Acquire Stake in Alacris, Gaining Access to Biomarker Pipeline for use in Personalized Healthcare Assays
1/11/2011
-
QIAGEN Inc. Supplies Point-of-Need Molecular Testing Devices for Animal Disease Surveillance in Emerging Countries
11/29/2010
-
QIAGEN Inc. Beats but Cuts Rev Guidance
11/10/2010
-
QIAGEN Inc. Inks Deal with Abbott GmbH
10/18/2010
-
QIAGEN Inc. Prepares To Expand As Earnings Continue To Grow
8/17/2010
-
Biosearch Technologies Expands Licensing of QIAGEN Inc. Scorpions(R) Patents to Manufacture Primer Assays for Research, Applied Markets and Infectious Diseases
8/12/2010
-
Roche Obtains Co-Exclusive License to Develop PCR Assays Detecting Mutations in the PI3K Oncogene From QIAGEN Inc.
7/13/2010
-
QIAGEN Inc. Announces CE Marking of its careHPV Test for Developing Countries
7/6/2010
-
QIAGEN Inc. Wins 2010 Mediscience Award for "Transaction of the Year"
6/28/2010
-
QIAGEN Inc. Expands Partnership with Genome Diagnostics for Development of New Tests for Applications in Prevention and Personalized Healthcare
6/17/2010
-
QIAGEN Inc. Posts 2009 Annual Report on Its Website
6/2/2010
-
QIAGEN Inc. and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics
5/27/2010
-
ifp Institut für Produktqualität Enters Global Cooperation with QIAGEN Inc. to Market its Food Tests
5/26/2010